Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis

Currently, a large number of highly effective biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are used for the treatment of rheumatoid arthritis (RA). However, in addition to effectiveness, it is necessary to evaluate the risk of adverse events (AEs)...

Full description

Bibliographic Details
Main Authors: E. N. Koltsova, G. V. Lukina, E. I. Schmidt, K. A. Lytkina, E. V. Zhilyaev
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2022-12-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/1368